Switching approach in the management of schizophrenia patients

International Clinical Psychopharmacology

Volumn 15, Issue SUPPL. 4, 2000, Pages

  Peuskens, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Amisulpride; Clozapine; Compliance; Depressive symptoms; Drug interactions; Education; Negative symptoms; Olanzapine; Positive symptoms; Quality of life; Quetiapine; Refractory; Relapse; Risperidone; Weight gain; Withdrawal; Ziprasidone; Zotepine

Indexed keywords

AMISULPRIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT;

CONFERENCE PAPER; DEPRESSION; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; DRUG TOLERABILITY; HUMAN; HYPOTENSION; NEGATIVE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA; SOMNOLENCE;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT CARE PLANNING; PROGNOSIS; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0034471682     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Practice guidelines for the treatment of patients with schizophrenia
2. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia
3. Changing antipsychotic medication: Guidelines on the transition to treatment with risperidone
4. Side effect profiles of new antipsychotic agents
5. Tardive dyskinesia and atypical antipsychotic drugs
6. Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases
7. Safety of amisulpride: A review of 11 clinical studies
8. Medication use in the hospitalised schizophrenic patients in Belgium
9. Antipsychotic withdrawal symptoms: Phenomenology and pathophysiology
10. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design
11. Treatment of schizophrenia: The expert consensus guideline series
12. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: Three efficacy studies
13. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures
14. Withdrawal syndromes associated with antipsychotic drugs
15. Neuroleptic withdrawal in schizophrenic patients. A review of the literature
16. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia
17. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis
18. Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients
19. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs
20. Management of treatment-resistant patients with schizophrenia
21. Clozapine withdrawal: Serotonergic or dopaminergic mechanisms?
22. Clinical update on amisulpride in deficit schizophrenia
23. Amisulpride: From animal pharmacology to therapeutic action
24. Clinical implications of clozapine discontinuation: Report of an NIMH workshop
25. Persistence of plasma neuroleptic levels after drug discontinuation
26. Switching from typical to atypical antipsychotics
27. Neuroleptic discontinuation syndromes
28. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
29. Switching antipsychotic medications